Brian Orelli, PhD

XOMA falls after phase 2 trials fail, but its anti-inflammatory drug gevokizumab still has potential in other diseases.

If approved, empagliflozin from Eli Lilly and Boehringer Ingelheim Pharmaceuticals would compete against AstraZeneca's Forxiga and Johnson & Johnson's Invokana.

The FDA doesn't seem to have made up its mind about an accelerated approval for Sarepta Therapeutics' eteplirsen despite a clinical trial failure by competitors Prosensa and GlaxoSmithKline.

Amarin sues AstraZeneca over its fish oil pill Epanova. If the companies can't reach sales close to GlaxoSmithKline's Lovaza, it will be for naught.

Despite a lackluster quarter where it trailed rivals Johnson & Johnson and Medication, investors sent sales of Dendreon up 15%.

Arena traded down after earnings, but investors have nothing to be afraid of. Not even VIVUS obesity drug.

Amarin has to diferentiate Vasecepa from GlaxoSmithKline's and AbbVie's drugs or cuts costs massively.

Since returning to market, ARIAD Pharmaceuticals has captured about half of the patients on Iclusig before it went off the market, but it'll have a hard time competing with Novartis' and Bristol-Myers Squibb's leukemia drugs.

InterMune succeeds where Gilead and Novartis failed. Its IPF drug Esbriet looks destined for approval.

Amarin's patents holding up in court and being able to compete with GlaxoSmithKline's Lovaza for patients are much bigger deals.

Hepatitis C is important, but only for two of the thee points.

Decoupling health care from employment is a good move.

Eli Lilly, Bristol-Myers Squibb, Roche, AstraZeneca, and Merck top the charts.

Arena and VIVUS have signed deals with insurers and pharmacy benefit managers for their obesity drugs, but people on government programs like Medicare are largely excluded.

Merck's V503 protects against more HPV types than Merck's Gardasil or GlaxoSmithKline's Cervarix.

The inhaled insulin drugmaker faces an FDA review in April, but when will AstraZeneca, Merck or one of the other major drugmakers step up and license Afrezza?

It isn't clear whether Prana Biotechnology's PBT2 is effective in Huntington Disease. We'll know whether it will press on -- like Merck and Eli Lilly have done -- in Alzheimer's disease next month.

Myraid Genetics, Sarepta Therapeutics, Questcor Pharmaceuticals, Ziopharm Oncology, and MannKind top the list of the most shorted biotechs.

This video discusses Amgen's evolocumab, Rengeneron Pharmaceuticals and Sanofi's alirocumab, and the rest of the PCSK9 inhibitors.

A video discussing Amarin's issues, compounded by competition from GlaxoSmithKline and issues over trails run on drugs from Merck and AbbVie.